e-ISSN 1309-2545      ISSN 1301-062X
TR    ENG
 

Download Current Issue.

Volume : 27 Issue : 3 Year : 2021

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login
Turkish Journal of Neurology Indexed By
  Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis? [Turk J Neurol]
Turk J Neurol. 2021; 27(3): 257-262 | DOI: 10.4274/tnd.2021.81073  

Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis?

Arife Çimen Atalar1, Mesrure Köseoğlu2, Nurettin Yavuz1, Yüksel Erdal1, Osman Oğuz3, Ufuk Emre1
1University of Health Sciences Turkey, Istanbul Training and Research Hospital, Clinic of Neurology, Istanbul, Turkey
2University of Health Sciences Turkey, Istanbul Bakirkoy Prof. Dr. Mazhar Osman Mental Health and Nervous Diseases Training and Research Hospital, Clinic of Neurology, Istanbul, Turkey
3University of Health Sciences Turkey, Istanbul Training and Research Hospital, Clinic of Biochemistry, Istanbul, Turkey

Objective: Multiple sclerosis (MS) is a chronic degenerative and inflammatory disease leading to axonal damage and demyelination in the central nervous system. Although the pathogenesis is still controversial, it is accepted that there is an immune-mediated inflammatory response. Endothelial cell specific molecule-1 (ESM-1) (endocan) is expressed by endothelial cells under the control of cytokines, and increases in inflammatory processes involving the vascular endothelium. In this study, we aimed to compare serum endocan levels along with other hematologic inflammatory markers [such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] in patients with relapsing-remitting MS (RRMS) and healthy controls. We also aimed at investigating the role of vascular endothelial dysfunction in RRMS.
Materials and Methods: We enrolled 64 patients with RRMS in the remission period, and 37 healthy controls in the study. We investigated hematologic parameters (ESR, CRP) and serum ESM-1 levels by enzyme-linked immunosorbent assay. Results were compared between two groups statistically.
Results: The CRP and ESR had no significant difference between patients and controls (p=0.861 and p=0.76 respectively). Serum endocan levels of the patient group were significantly higher than the healthy controls (p=0.045). RRMS patients with or without treatment and comorbid diseases showed no significant difference in serum endocan levels (p=0.565 and p=0.169 respectively). The predictive value of endocan was 62.0%, cut-off value was 9124.7326 pg/l, sensitivity was 68.8%, and specificity was 54.1%.
Conclusion: We demonstrated higher serum endocan levels in patients with RRMS in remission period, confirming the role of vascular inflammation. Further studies including larger patient cohorts are needed to support our results.

Keywords: endocan, ESM-1, multiple sclerosis, biomarker, inflammation


Arife Çimen Atalar, Mesrure Köseoğlu, Nurettin Yavuz, Yüksel Erdal, Osman Oğuz, Ufuk Emre. Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis?. Turk J Neurol. 2021; 27(3): 257-262

Corresponding Author: Arife Çimen Atalar, Türkiye


TOOLS
English Full Text
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
© Copyright 2021 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale